Sillajen CEO Kim Jae-kyung speaks during a press conference at the Press Center in Jung District, central Seoul, on Tuesday.YONHAP
Sillajen will start recruiting patients for the first phase clinical trial of a new oncology drug, the pharmaceutical company said Tuesday.
This is Sillajen's first major project since it was allowed to resume stock trading in October after a more than two-year suspension. Plans for the trial were described at a press conference at the Press Center in Jung District, central Seoul, on Tuesday.
The suspension started in May 2020 when former executives of Sillajen were charged with embezzlement and breach of trust.
The drug, called BAL0891, has the potential to disrupt cell division and lead to death of tumor cells. Sillajen had previously acquired a license for BAL0891 for $14 million from Switzerland-based Basilea Pharmaceutica International.
The Mary Crowley Cancer Research, the Montefiore Medical Center and the OHSU Knight Cancer Institute in the United States will be involved in the first phase trial of BAL0891. Sillajen also said that the company is looking for hospitals in Korea to participate.